Bluejay Diagnostics (NASDAQ:BJDX) issued a corporate update on Friday detailing its 2026 operational roadmap, focused on the regulatory path for its Symphony™ System and its flagship IL-6 clinical test.
The Acton, Massachusetts-based diagnostics firm is prioritizing the completion of its SYMON™ II clinical study, a critical step toward an FDA 510(k) submission.
The study evaluates the Symphony IL-6 test’s ability to provide rapid, near-patient results for patients at risk of sepsis, aiming to reduce the current laboratory turnaround time from hours to minutes.
Financially, Bluejay reported a net loss of $6.8 million for the 2025 fiscal year, ending the period with approximately $5.2 million in cash and $6 million in stockholders' equity.
The company bolstered its balance sheet through 2025 with $8.3 million in combined gross proceeds from a private placement (PIPE) and a warrant-inducement exercise.
With approximately 972,000 common shares outstanding following the conversion of pre-funded warrants, management indicated a requirement for at least $20 million in additional capital through 2027 to fund full-scale commercialization and supply chain readiness.